[go: up one dir, main page]

CL2008003218A1 - Método para la purificación de un anticuerpo a partir de una composición que comprende el anticuerpo y al menos un contaminante. - Google Patents

Método para la purificación de un anticuerpo a partir de una composición que comprende el anticuerpo y al menos un contaminante.

Info

Publication number
CL2008003218A1
CL2008003218A1 CL2008003218A CL2008003218A CL2008003218A1 CL 2008003218 A1 CL2008003218 A1 CL 2008003218A1 CL 2008003218 A CL2008003218 A CL 2008003218A CL 2008003218 A CL2008003218 A CL 2008003218A CL 2008003218 A1 CL2008003218 A1 CL 2008003218A1
Authority
CL
Chile
Prior art keywords
antibody
purification
contaminant
composition
deadlined
Prior art date
Application number
CL2008003218A
Other languages
English (en)
Inventor
Benedicte Andree O'connor Deborah Ann Safta Aurelia Sharma Mandakini Lebreton
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40262967&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2008003218(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of CL2008003218A1 publication Critical patent/CL2008003218A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/18—Ion-exchange chromatography
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/36—Extraction; Separation; Purification by a combination of two or more processes of different types
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
    • C07K16/065—Purification, fragmentation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Analytical Chemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)

Abstract

SE DESCRIBE UN MÉTODO PARA LA PURIFICACIÓN DE ANTICUERPO POR CROMATOGRAFIA DE INTERCAMBIO CATIÓNICO EN EL QUE EL PASO DE LAVADO A PH ELEVADO SE UTILIZA PARA ELIMINAR LOS CONTAMINANTES ANTES DE ELUIR EL ANTICUERPO DESEADO UTILIZANDO UNA SOLUCIÓN TAMPÓN DE ELUCIÓN CON CONDUCTIVIDAD AUMENTADA        
CL2008003218A 2007-10-30 2008-10-29 Método para la purificación de un anticuerpo a partir de una composición que comprende el anticuerpo y al menos un contaminante. CL2008003218A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US98382507P 2007-10-30 2007-10-30

Publications (1)

Publication Number Publication Date
CL2008003218A1 true CL2008003218A1 (es) 2009-03-06

Family

ID=40262967

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2008003218A CL2008003218A1 (es) 2007-10-30 2008-10-29 Método para la purificación de un anticuerpo a partir de una composición que comprende el anticuerpo y al menos un contaminante.

Country Status (32)

Country Link
US (3) US20090148435A1 (es)
EP (4) EP2565206B1 (es)
JP (5) JP5237382B2 (es)
KR (3) KR20140015166A (es)
CN (3) CN103554215B (es)
AR (2) AR069097A1 (es)
AU (1) AU2008318865B2 (es)
BR (1) BRPI0817182A2 (es)
CA (1) CA2703279C (es)
CL (1) CL2008003218A1 (es)
CO (1) CO6280422A2 (es)
CY (1) CY1116129T1 (es)
DK (3) DK2215117T4 (es)
ES (3) ES2572958T3 (es)
HK (1) HK1221234A1 (es)
HR (2) HRP20150282T4 (es)
HU (3) HUE027668T2 (es)
IL (4) IL205310A0 (es)
ME (1) ME02101B (es)
MX (1) MX2010004740A (es)
NZ (1) NZ584839A (es)
PE (1) PE20091434A1 (es)
PH (1) PH12013501128A1 (es)
PL (3) PL2215117T5 (es)
PT (1) PT2215117E (es)
RS (1) RS53850B2 (es)
RU (1) RU2498991C2 (es)
SG (2) SG10201401690XA (es)
SI (3) SI2565206T1 (es)
TW (2) TWI448330B (es)
WO (1) WO2009058812A1 (es)
ZA (2) ZA201002850B (es)

Families Citing this family (92)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2708095T3 (es) 2003-11-05 2019-04-08 Roche Glycart Ag Anticuerpos de CD20 con afinidad de unión a receptor de Fc y función efectora incrementadas
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
BRPI0518104B8 (pt) * 2005-01-21 2021-05-25 Genentech Inc artigo industrializado e uso de anticorpo her2
RU2404806C2 (ru) 2005-02-23 2010-11-27 Дженентек, Инк. Продление времени до прогрессирования заболевания или продолжительности жизни у онкологических больных с применением ингибиторов димеризации her
US8911964B2 (en) 2006-09-13 2014-12-16 Abbvie Inc. Fed-batch method of making human anti-TNF-alpha antibody
CN103276033A (zh) 2006-09-13 2013-09-04 雅培制药有限公司 细胞培养改良
CA2677108A1 (en) 2007-03-02 2008-09-12 Genentech, Inc. Predicting response to a her inhibitor
MX2010004740A (es) 2007-10-30 2010-05-27 Genentech Inc Purificacion de anticuerpos por cromatografia de intercambio cationico.
TWI472339B (zh) 2008-01-30 2015-02-11 Genentech Inc 包含結合至ｈｅｒ２結構域ii之抗體及其酸性變異體的組合物
BRPI0812682A2 (pt) 2008-06-16 2010-06-22 Genentech Inc tratamento de cáncer de mama metastático
AR073295A1 (es) 2008-09-16 2010-10-28 Genentech Inc Metodos para tratar la esclerosis multiple progresiva. articulo de fabricacion.
US8268314B2 (en) 2008-10-08 2012-09-18 Hoffmann-La Roche Inc. Bispecific anti-VEGF/anti-ANG-2 antibodies
SG10201702922VA (en) 2008-10-20 2017-06-29 Abbvie Inc Isolation and purification of antibodies using protein a affinity chromatography
RU2551237C2 (ru) 2008-10-20 2015-05-20 Эббви Инк Инактивация вируса при очистке антител
AR078161A1 (es) * 2009-09-11 2011-10-19 Hoffmann La Roche Formulaciones farmaceuticas muy concentradas de un anticuerpo anti cd20. uso de la formulacion. metodo de tratamiento.
WO2011037983A1 (en) 2009-09-23 2011-03-31 Medarex, Inc. Cation exchange chromatography
KR20190143480A (ko) * 2010-02-23 2019-12-30 제넨테크, 인크. 난소암의 치료를 위한 항혈관신생 요법
AR080794A1 (es) 2010-03-26 2012-05-09 Hoffmann La Roche Anticuerpos bivalentes biespecificos anti- vegf/ anti-ang-2
SG184195A1 (en) * 2010-03-30 2012-11-29 Janssen Biotech Inc Humanized il-25 antibodies
EP2569436B8 (en) 2010-05-14 2019-10-30 Oregon Health & Science University Recombinant hcmv and rhcmv vectors and uses thereof
EP3299380B1 (en) * 2010-05-25 2024-08-28 F. Hoffmann-La Roche AG Methods of purifying polypeptides
GB201012603D0 (en) 2010-07-27 2010-09-08 Ucb Pharma Sa Protein purification
BR112013012422A2 (pt) * 2010-12-21 2016-08-30 Hoffmann La Roche "método para produzir uma preparação de anticorpo e anticorpo anti-her2"
KR102058254B1 (ko) 2011-03-29 2019-12-20 글락소스미스클라인 엘엘씨 단백질 정제용 완충제 시스템
US20140107321A1 (en) * 2011-05-26 2014-04-17 Dr. Reddy's Laboratories Limited Purification of antibodies
RS57397B8 (sr) 2011-06-10 2020-01-31 Univ Oregon Health & Science Cmv glikoproteini i rekombinantni vektori
WO2013054250A1 (en) * 2011-10-10 2013-04-18 Dr Reddy's Laboratories Limited Purification method
PT4241849T (pt) 2011-10-14 2024-10-30 Hoffmann La Roche Utilizações do inibidor da dimerização de her2 pertuzumab e artigo de fabrico que inclui o mesmo
RU2478646C1 (ru) * 2011-11-28 2013-04-10 Федеральное государственное бюджетное учреждение науки Институт молекулярной биологии им.В.А.Энгельгардта Российской академии наук (ИМБ РАН) Способ получения высокоаффинных поликлональных антител
CA2859376C (en) 2011-12-22 2022-04-19 Genentech, Inc. Use of ion exchange chromatography for improving downstream chromatography steps for purification of antibodies
RS62509B1 (sr) 2012-07-13 2021-11-30 Roche Glycart Ag Bispecifična anti-vegf/anti-ang-2 antitela i njihova upotreba u lečenju očnih vaskularnih bolesti
WO2014034644A1 (ja) * 2012-08-27 2014-03-06 旭化成メディカル株式会社 温度応答性クロマトグラフィーによる抗体の精製方法
CN103217499B (zh) * 2013-01-15 2015-12-02 珠海市丽珠单抗生物技术有限公司 一种测定免疫球蛋白电荷异构体的糖基化和末端修饰情况的方法
HK1219964A1 (zh) * 2013-03-08 2017-04-21 Genzyme Corporation 治疗性蛋白药物物质的整合连续制造
UY35517A (es) 2013-04-04 2014-10-31 Mabxience S A Un procedimiento para aumentar la formación de ácido piroglutamico de una proteína
AR095863A1 (es) 2013-04-16 2015-11-18 Genentech Inc Variantes de pertuzumab, su evaluación, método de tratamiento, método de preparación y artículo de fabricación
WO2015064971A1 (ko) * 2013-10-30 2015-05-07 (주)셀트리온 양이온 교환 크로마토그래피를 이용한 항체의 아형 분리 방법
CN104628846B (zh) * 2013-11-06 2019-12-06 三生国健药业（上海）股份有限公司 重组蛋白质的纯化方法
SG11201602995VA (en) * 2013-11-25 2016-05-30 Seattle Genetics Inc Preparing antibodies from cho cell cultures for conjugation
TWI709569B (zh) 2014-01-17 2020-11-11 美商健臻公司 無菌層析樹脂及其用於製造方法的用途
TWI709570B (zh) 2014-01-17 2020-11-11 美商健臻公司 無菌層析法及製法
KR102567586B1 (ko) 2014-02-04 2023-08-16 바이오젠 엠에이 인코포레이티드 번역 후 변형을 강화시키기 위한 통류 방식 양이온 교환 크로마토그래피의 용도
HRP20200711T1 (hr) 2014-03-10 2020-07-24 Richter Gedeon Nyrt. Pročišćavanje imunoglobulina korištenjem koraka prethodnog čišćenja
CN105017418B (zh) * 2014-03-27 2021-02-23 上海药明康德新药开发有限公司 单克隆抗体纯化工艺方法
CA2946860A1 (en) 2014-04-25 2015-10-29 Genentech, Inc. Methods of treating early breast cancer with trastuzumab-mcc-dm1 and pertuzumab
NZ728208A (en) 2014-07-16 2018-07-27 Univ Oregon Health & Science Human cytomegalovirus comprising exogenous antigens
CN105315369B (zh) * 2014-07-25 2020-03-13 山东博安生物技术有限公司 利用阳离子交换层析纯化蛋白质
AU2016233557B2 (en) * 2015-03-13 2021-06-24 Bristol-Myers Squibb Company Use of alkaline washes during chromatography to remove impurities
FI3302551T3 (fi) 2015-05-30 2024-08-27 Hoffmann La Roche Menetelmiä her2-positiivisen, aiemmin hoitamattoman metastaattisen rintasyövän hoitamiseksi
KR101657690B1 (ko) * 2015-06-05 2016-09-19 주식회사 녹십자홀딩스 혈장 유래 b형 간염 사람 면역글로불린 제제의 제조방법
WO2017087280A1 (en) 2015-11-16 2017-05-26 Genentech, Inc. Methods of treating her2-positive cancer
MA43285A (fr) 2015-11-20 2018-09-26 Univ Oregon Health & Science Vecteurs cmv comprenant des éléments de reconnaissance des microarn
GB201600512D0 (en) 2016-01-12 2016-02-24 Univ York Recombinant protein production
CA3019426A1 (en) 2016-04-15 2017-10-19 The Trustees Of The University Of Pennsylvania Compositions for treatment of wet age-related macular degeneration
US10654922B2 (en) * 2016-05-13 2020-05-19 Askgene Pharma Inc. Angiopoietin 2, VEGF dual antagonists
PL3484911T3 (pl) * 2016-07-15 2021-03-08 F. Hoffmann-La Roche Ag Sposób oczyszczania PEGylowanej erytropoetyny
CN106222222B (zh) * 2016-08-08 2019-10-29 湖北医药学院 一种重组人白血病抑制因子的制备方法
WO2018045587A1 (zh) * 2016-09-12 2018-03-15 广东东阳光药业有限公司 一种抗vegf类单克隆抗体的纯化方法
CN106380519B (zh) * 2016-10-17 2019-11-01 深圳万乐药业有限公司 一种单克隆抗体的纯化方法
IL266011B2 (en) 2016-10-18 2024-03-01 Univ Oregon Health & Science Cytomegalovirus vectors eliciting t cells restricted by major histocompatibility complex e molecules
WO2018078158A1 (en) * 2016-10-31 2018-05-03 Hexal Ag Antibody preparation
WO2018125589A1 (en) 2016-12-28 2018-07-05 Genentech, Inc. Treatment of advanced her2 expressing cancer
SI3570884T1 (sl) 2017-01-17 2021-02-26 Genentech, Inc. Subkutane formulacije protiteles HER2
CN114984206A (zh) 2017-03-02 2022-09-02 基因泰克公司 Her2阳性乳腺癌的辅助治疗
BE1025090B1 (fr) 2017-03-30 2018-10-29 Univercells Sa Procede et kit de purification de proteines
WO2018190677A2 (en) * 2017-04-14 2018-10-18 Cj Healthcare Corporation Method for purifying analogous antibody using cation-exchange chromatography
WO2018200505A1 (en) 2017-04-24 2018-11-01 Genentech, Inc. Erbb2/her2 mutations in the transmbrane or juxtamembrane domain
WO2018237159A1 (en) * 2017-06-21 2018-12-27 Cephalon, Inc. Cation exchange chromatography wash buffer
TWI826393B (zh) * 2017-09-22 2023-12-21 美商免疫遺傳股份有限公司 使用陽離子交換層析法分離三輕鏈抗體
CN110272491B (zh) * 2018-03-13 2023-01-24 江苏恒瑞医药股份有限公司 一种抗pd-1抗体的纯化工艺
KR20200136464A (ko) * 2018-03-29 2020-12-07 브리스톨-마이어스 스큅 컴퍼니 단량체성 모노클로날 항체를 정제하는 방법
CN112105927B (zh) * 2018-05-08 2024-06-25 沃特世科技公司 可用于pH梯度阳离子交换色谱法的方法、组合物和试剂盒
CN109053895B (zh) 2018-08-30 2020-06-09 中山康方生物医药有限公司 抗pd-1-抗vegfa的双功能抗体、其药物组合物及其用途
EP3843869A1 (en) 2018-08-31 2021-07-07 Genzyme Corporation Sterile chromatography resin and use thereof in manufacturing processes
EP3643322A1 (en) * 2018-10-26 2020-04-29 Mabion SA Low aggregate anti cd20 ligand formulation
MA54052A (fr) 2018-10-29 2022-02-09 Hoffmann La Roche Formulation d'anticorps
CN109320611B (zh) * 2018-10-31 2022-06-03 鼎康(武汉)生物医药有限公司 一种人鼠嵌合单克隆抗体生物类似药的纯化方法
CN112206327A (zh) * 2019-07-12 2021-01-12 上海药明生物技术有限公司 一种抗体偶联药物的制备及其高通量筛选方法
US20220396598A1 (en) * 2019-10-14 2022-12-15 Pierce Biotechnology, Inc. Peptide purification formulations and methods
MX2022005594A (es) * 2019-11-07 2022-06-09 Amgen Inc Lavados de salinidad elevada durante cromatografia de intercambio cationico para eliminar impurezas relacionadas con el producto.
MX2022006330A (es) * 2019-11-25 2022-08-17 Akeso Biopharma Inc Anticuerpo biespecífico anti-pd-1 anti-vegfa, composición farmacéutica y uso del mismo.
KR102153258B1 (ko) * 2020-02-21 2020-09-07 프레스티지바이오로직스 주식회사 베바시주맙 정제의 최적화된 방법
EP4130045A4 (en) * 2020-03-25 2023-12-27 Jiangsu Hengrui Pharmaceuticals Co., Ltd. METHOD FOR PREPARING AN ANTIBODY-DRUG CONJUGATE
KR20250151568A (ko) 2020-06-29 2025-10-21 제넨테크, 인크. 퍼투주맙 + 트라스투주맙 고정 용량 조합
US11416468B2 (en) * 2020-07-21 2022-08-16 International Business Machines Corporation Active-active system index management
CA3236006A1 (en) 2021-11-16 2023-05-25 Genentech, Inc. Methods and compositions for treating systemic lupus erythematosus (sle) with mosunetuzumab
CN114591438B (zh) * 2022-04-25 2023-12-05 达石药业(广东)有限公司 一种采用阳离子交换层析法纯化双特异性抗体的方法
CN120112310A (zh) * 2022-10-26 2025-06-06 日本医事物理股份有限公司 放射性药物组合物的制造方法
CN115850493B (zh) * 2022-11-08 2024-03-12 江苏耀海生物制药有限公司 一种二价纳米抗体Cablivi的分离纯化方法
CN117756878A (zh) * 2023-12-26 2024-03-26 康日百奥生物科技(苏州)有限公司 抗体层析分离方法及应用
WO2025193804A1 (en) * 2024-03-12 2025-09-18 Massachusetts Eye And Ear Infirmary Methods and materials for treating ocular neovascular diseases
WO2025232755A1 (zh) * 2024-05-07 2025-11-13 南京蓬勃生物科技有限公司 一种使用阳离子交换层析纯化目标蛋白的方法

Family Cites Families (109)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
USRE30985E (en) 1978-01-01 1982-06-29 Serum-free cell culture media
US4515893A (en) 1979-04-26 1985-05-07 Ortho Pharmaceutical Corporation Hybrid cell line for producing complement-fixing monoclonal antibody to human T cells
GB2070818A (en) 1980-02-04 1981-09-09 Philips Electronic Associated Regulated power supply for an image intensifier
WO1984002129A1 (fr) 1982-11-22 1984-06-07 Takeda Chemical Industries Ltd Proteine de l'interferon immun humain et son procede de preparation
US4560655A (en) 1982-12-16 1985-12-24 Immunex Corporation Serum-free cell culture medium and process for making same
US4657866A (en) 1982-12-21 1987-04-14 Sudhir Kumar Serum-free, synthetic, completely chemically defined tissue culture media
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
DD266710A3 (de) 1983-06-06 1989-04-12 Ve Forschungszentrum Biotechnologie Verfahren zur biotechnischen Herstellung van alkalischer Phosphatase
US4767704A (en) 1983-10-07 1988-08-30 Columbia University In The City Of New York Protein-free culture medium
US4753894A (en) 1984-02-08 1988-06-28 Cetus Corporation Monoclonal anti-human breast cancer antibodies
US6054561A (en) 1984-02-08 2000-04-25 Chiron Corporation Antigen-binding sites of antibody molecules specific for cancer antigens
US5169774A (en) * 1984-02-08 1992-12-08 Cetus Oncology Corporation Monoclonal anti-human breast cancer antibodies
WO1986002068A1 (fr) 1984-09-26 1986-04-10 Takeda Chemical Industries, Ltd. Separation mutuelle de proteines
US4879231A (en) 1984-10-30 1989-11-07 Phillips Petroleum Company Transformation of yeasts of the genus pichia
US5196323A (en) * 1985-04-27 1993-03-23 Boehringer Ingelheim International Gmbh Process for preparing and purifying alpha-interferon
GB8516415D0 (en) 1985-06-28 1985-07-31 Celltech Ltd Culture of animal cells
US5525338A (en) 1992-08-21 1996-06-11 Immunomedics, Inc. Detection and therapy of lesions with biotin/avidin conjugates
US5091178A (en) 1986-02-21 1992-02-25 Oncogen Tumor therapy with biologically active anti-tumor antibodies
US4927762A (en) 1986-04-01 1990-05-22 Cell Enterprises, Inc. Cell culture medium with antioxidant
GB8610600D0 (en) 1986-04-30 1986-06-04 Novo Industri As Transformation of trichoderma
CA1283072C (en) 1986-12-01 1991-04-16 Timothy Durance Process for the isolation and separation of lysozyme and avidin from eggwhite
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
US5451662A (en) 1987-10-23 1995-09-19 Schering Corporation Method of purifying protein
US5118796A (en) 1987-12-09 1992-06-02 Centocor, Incorporated Efficient large-scale purification of immunoglobulins and derivatives
US5091313A (en) 1988-08-05 1992-02-25 Tanox Biosystems, Inc. Antigenic epitopes of IgE present on B cell but not basophil surface
US5720937A (en) 1988-01-12 1998-02-24 Genentech, Inc. In vivo tumor detection assay
JP3040121B2 (ja) 1988-01-12 2000-05-08 ジェネンテク，インコーポレイテッド 増殖因子レセプターの機能を阻害することにより腫瘍細胞を処置する方法
IT1219874B (it) 1988-03-18 1990-05-24 Fidia Farmaceutici Utilizzazione del fattore di crescita nervoso umano e sue composizioni farmaceutiche
US5115101A (en) 1988-06-08 1992-05-19 Miles Inc. Removal of protein A from antibody preparations
JP2749167B2 (ja) 1988-06-21 1998-05-13 ジェネンテク，インコーポレイテッド 心筋梗塞の処置のための方法および治療用組成物
WO1990003430A1 (en) 1988-09-23 1990-04-05 Cetus Corporation Cell culture medium for enhanced cell growth, culture longevity and product expression
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
EP0402226A1 (en) 1989-06-06 1990-12-12 Institut National De La Recherche Agronomique Transformation vectors for yeast yarrowia
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US5112951A (en) * 1989-07-28 1992-05-12 Hybritech Incorporated Separation of anti-metal chelate antibodies
US5110913A (en) 1990-05-25 1992-05-05 Miles Inc. Antibody purification method
EP0467466A1 (en) * 1990-07-16 1992-01-22 Eastman Kodak Company Method for the purification of immunoreactive labeled thyroxine conjugates
US5122469A (en) 1990-10-03 1992-06-16 Genentech, Inc. Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
DE122004000008I1 (de) 1991-06-14 2005-06-09 Genentech Inc Humanisierter Heregulin Antikörper.
EP0602126B1 (en) 1991-08-14 2003-03-05 Genentech, Inc. Immunoglobulin variants for specific fc epsilon receptors
EP0604580A1 (en) 1991-09-19 1994-07-06 Genentech, Inc. EXPRESSION IN E. COLI OF ANTIBODY FRAGMENTS HAVING AT LEAST A CYSTEINE PRESENT AS A FREE THIOL, USE FOR THE PRODUCTION OF BIFUNCTIONAL F(ab') 2? ANTIBODIES
ATE297465T1 (de) 1991-11-25 2005-06-15 Enzon Inc Verfahren zur herstellung von multivalenten antigenbindenden proteinen
JPH05202098A (ja) 1992-01-29 1993-08-10 Snow Brand Milk Prod Co Ltd 乳質原料から生理活性物質の製造法
ATE295420T1 (de) 1992-02-06 2005-05-15 Chiron Corp Marker für krebs und biosynthetisches bindeprotein dafür
US5279823A (en) 1992-06-08 1994-01-18 Genentech, Inc. Purified forms of DNASE
AU687755B2 (en) 1992-08-21 1998-03-05 Genentech Inc. Method for treating an LFA-1-mediated disorder
US5736137A (en) 1992-11-13 1998-04-07 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
PL174721B1 (pl) 1992-11-13 1998-09-30 Idec Pharma Corp Przeciwciało monoklonalne anty-CD20
US5595721A (en) 1993-09-16 1997-01-21 Coulter Pharmaceutical, Inc. Radioimmunotherapy of lymphoma using anti-CD20
WO1995016203A2 (en) 1993-12-10 1995-06-15 Genentech, Inc. Methods for diagnosis of allergy and screening of anti-allergy therapeutics
DK0739214T3 (da) 1994-01-18 1998-10-07 Genentech Inc Fremgangsmåde til behandling af parasitinfektionerunder anvendelse af IgE antagonister
US5429746A (en) 1994-02-22 1995-07-04 Smith Kline Beecham Corporation Antibody purification
CA2181787A1 (en) 1994-03-03 1995-09-08 Claire M. Doerschuk Anti-il-8 monoclonal antibodies for treatment of inflammatory disorders
US5534615A (en) 1994-04-25 1996-07-09 Genentech, Inc. Cardiac hypertrophy factor and uses therefor
IL117645A (en) 1995-03-30 2005-08-31 Genentech Inc Vascular endothelial cell growth factor antagonists for use as medicaments in the treatment of age-related macular degeneration
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
CA2222231A1 (en) 1995-06-07 1996-12-19 Imclone Systems Incorporated Antibody and antibody fragments for inhibiting the growth of tumors
US5714583A (en) 1995-06-07 1998-02-03 Genetics Institute, Inc. Factor IX purification methods
US6267958B1 (en) * 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
CA2242414C (en) 1996-01-23 2012-01-03 Genentech, Inc. Anti-cd18 antibodies for use against stroke
US7147851B1 (en) 1996-08-15 2006-12-12 Millennium Pharmaceuticals, Inc. Humanized immunoglobulin reactive with α4β7 integrin
ID26697A (id) 1996-11-15 2001-02-01 Genentech Inc Pemurnian neurotrofin
IL130143A0 (en) 1996-11-27 2000-06-01 Genentech Inc Humanized anti-CD11a antibodies
PT1864999E (pt) 1996-11-27 2009-06-25 Genentech Inc Purificação por afinidade de um polipéptido numa matriz de proteína a
SI0973804T1 (sl) 1997-04-07 2007-06-30 Genentech Inc Proti-VEGF protitelesa
DK1325932T5 (da) 1997-04-07 2005-10-03 Genentech Inc Anti-VEGF antistoffer
US20020032315A1 (en) 1997-08-06 2002-03-14 Manuel Baca Anti-vegf antibodies
EP1860187B1 (en) 1997-05-15 2011-07-13 Genentech, Inc. Apo-2 receptor
US5994511A (en) 1997-07-02 1999-11-30 Genentech, Inc. Anti-IgE antibodies and methods of improving polypeptides
CN1305896C (zh) 1998-05-06 2007-03-21 基因技术股份有限公司 用离子交换层析纯化蛋白质
DK1084136T3 (da) 1998-06-01 2005-01-03 Genentech Inc Adskillelse af monomere af et antistof fra dets multimere ved anvendelse af ionbytterchromatografi
AU753468B2 (en) 1998-06-09 2002-10-17 Csl Behring Ag Process for producing immunoglobulins for intravenous administration and other immunoglobulin products
GEP20104998B (en) 1999-06-25 2010-06-10 Genentech Inc Humanized antibody which binds erbb2 and blocks activation by ligand receptor of erbb2 (variants) and use of the composition comprising these antibodies methods for treating cancer
DK1226177T3 (da) 1999-10-29 2008-10-06 Genentech Inc Antistofsammensætninger mod anti-prostata stamcelle-antigen (PSCA) og anvendelser deraf
UA83458C2 (uk) 2000-09-18 2008-07-25 Байоджен Айдек Ма Інк. Виділений поліпептид baff-r (рецептор фактора активації в-клітин сімейства tnf)
US6417355B1 (en) 2001-04-11 2002-07-09 The United States Of America As Represented By The Secretary Of The Navy Geminal-dinitro-1-5 diazocine derivatives
GB0113179D0 (en) * 2001-05-31 2001-07-25 Novartis Ag Organic compounds
US7321026B2 (en) 2001-06-27 2008-01-22 Skytech Technology Limited Framework-patched immunoglobulins
US6770027B2 (en) * 2001-10-05 2004-08-03 Scimed Life Systems, Inc. Robotic endoscope with wireless interface
WO2003033658A2 (en) 2001-10-17 2003-04-24 Human Genome Sciences, Inc. Neutrokine-alpha and neutrokine-alpha splice variant
US20040093621A1 (en) 2001-12-25 2004-05-13 Kyowa Hakko Kogyo Co., Ltd Antibody composition which specifically binds to CD20
EP1519959B1 (en) 2002-02-14 2014-04-02 Immunomedics, Inc. Anti-cd20 antibodies and fusion proteins thereof and methods of use
AU2003251592A1 (en) * 2002-06-21 2004-01-06 Biogen Idec Inc. Buffered formulations for concentrating antibodies and methods of use thereof
ES2527616T3 (es) * 2002-09-11 2015-01-27 Genentech, Inc. Purificación de anticuerpos anti-HER2
CA2502552C (en) 2002-10-17 2019-02-12 Genmab A/S Human monoclonal antibodies against cd20
MXPA05006306A (es) 2002-12-13 2005-09-21 Mitra Medical Technology Ab Agentes de direccionamiento antilinfoma con funciones efectoras y de afinidad enlazados a traves de un reactivo trifuncional.
UA89350C2 (uk) 2002-12-16 2010-01-25 Дженентек, Інк. Гуманізоване антитіло, що зв'язує людський cd20
BR0317896A (pt) 2002-12-31 2005-12-06 Altus Pharmaceuticals Inc Complexos de cristais de proteìna e polìmeros iÈnicos
JPWO2004087761A1 (ja) * 2003-03-31 2006-07-27 麒麟麦酒株式会社 ヒトモノクローナル抗体およびヒトポリクローナル抗体の精製
EP2960251A1 (en) 2003-05-09 2015-12-30 Duke University CD20-specific antibodies and methods of employing same
AR044388A1 (es) 2003-05-20 2005-09-07 Applied Molecular Evolution Moleculas de union a cd20
AU2004263538B2 (en) 2003-08-08 2009-09-17 Immunomedics, Inc. Bispecific antibodies for inducing apoptosis of tumor and diseased cells
US8147832B2 (en) 2003-08-14 2012-04-03 Merck Patent Gmbh CD20-binding polypeptide compositions and methods
KR100524074B1 (ko) 2003-10-01 2005-10-26 삼성전자주식회사 베젤 구조를 가지는 전자기기
TW200533357A (en) † 2004-01-08 2005-10-16 Millennium Pharm Inc 2-(amino-substituted)-4-aryl pyrimidines and related compounds useful for treating inflammatory diseases
CN101022829A (zh) * 2004-04-16 2007-08-22 健泰科生物技术公司 用抗cd20抗体治疗多软骨炎和多发性单神经炎
RU2006140374A (ru) * 2004-04-16 2008-05-27 Дженентек, Инк. (Us) Лечение нарушений
KR20070100307A (ko) * 2004-12-22 2007-10-10 제넨테크, 인크. 가용성 다중 막관통 단백질의 생산 방법
CN104610422A (zh) * 2005-03-11 2015-05-13 惠氏公司 弱分配层析的方法
US7825223B2 (en) * 2005-06-17 2010-11-02 Janssen Alzheimer Immunotherapy Methods of purifying anti A β antibodies
WO2007028154A2 (en) * 2005-09-02 2007-03-08 Northwestern University Encapsulated arsenic drugs
JP2009530378A (ja) * 2006-03-20 2009-08-27 メダレックス インコーポレーティッド タンパク質精製法
EP2738178A1 (en) † 2006-04-05 2014-06-04 AbbVie Biotechnology Ltd Antibody purification
JP2010501623A (ja) * 2006-08-28 2010-01-21 アレス トレーディング ソシエテ アノニム Ｆｃ含有タンパク質の精製法
US8620738B2 (en) 2006-08-31 2013-12-31 Visa U.S.A. Inc Loyalty program incentive determination
EP2068923A4 (en) * 2007-03-30 2010-11-24 Medimmune Llc ANTIBODIES HAVING REDUCED DEAMIDATION PROFILES
MX2010004740A (es) 2007-10-30 2010-05-27 Genentech Inc Purificacion de anticuerpos por cromatografia de intercambio cationico.
US9813410B2 (en) 2014-06-26 2017-11-07 Rakuten, Inc. Information processing apparatus, information processing method, and information processing program

Also Published As

Publication number Publication date
US20180118781A1 (en) 2018-05-03
RU2010121816A (ru) 2011-12-10
IL205310A0 (en) 2010-12-30
ES2666170T3 (es) 2018-05-03
ES2533266T5 (es) 2018-04-18
HUE037409T2 (hu) 2018-08-28
DK2215117T4 (en) 2018-04-09
IL239495B (en) 2019-09-26
CN103554215B (zh) 2016-06-15
MX2010004740A (es) 2010-05-27
PT2215117E (pt) 2015-04-01
ZA201102169B (en) 2012-12-27
IL234902A0 (en) 2014-11-30
EP2565206A3 (en) 2013-11-06
CN101889025B (zh) 2013-11-13
SI2840090T1 (en) 2018-05-31
JP2013173747A (ja) 2013-09-05
CO6280422A2 (es) 2011-05-20
SG10201401690XA (en) 2014-06-27
PH12013501128A1 (en) 2015-12-02
NZ584839A (en) 2012-07-27
HUE027668T2 (en) 2016-11-28
TW201512216A (zh) 2015-04-01
CA2703279A1 (en) 2009-05-07
ES2572958T3 (es) 2016-06-03
HK1143821A1 (en) 2011-01-14
SI2215117T2 (en) 2018-04-30
ES2533266T3 (es) 2015-04-08
JP5885864B2 (ja) 2016-03-16
SG175597A1 (en) 2011-11-28
HK1182401A1 (en) 2013-11-29
PL2840090T3 (pl) 2018-07-31
HRP20180943T1 (hr) 2018-08-10
DK2840090T3 (en) 2018-04-23
TW200927289A (en) 2009-07-01
US20090148435A1 (en) 2009-06-11
BRPI0817182A2 (pt) 2015-03-17
AR069097A1 (es) 2009-12-30
AU2008318865A1 (en) 2009-05-07
AR111171A2 (es) 2019-06-12
RS53850B2 (sr) 2018-07-31
HRP20150282T1 (hr) 2015-06-19
KR20140015166A (ko) 2014-02-06
EP2565206B1 (en) 2016-03-30
WO2009058812A1 (en) 2009-05-07
JP5237382B2 (ja) 2013-07-17
JP2017019790A (ja) 2017-01-26
ZA201002850B (en) 2011-07-27
TWI554517B (zh) 2016-10-21
HUE024877T2 (en) 2016-02-29
CN103554215A (zh) 2014-02-05
JP2015145371A (ja) 2015-08-13
JP2015155406A (ja) 2015-08-27
ME02101B (me) 2015-10-20
SI2565206T1 (sl) 2016-07-29
HRP20150282T4 (hr) 2018-08-10
IL239495A0 (en) 2015-08-31
KR101241486B1 (ko) 2013-03-15
EP2565206A2 (en) 2013-03-06
US20150056196A1 (en) 2015-02-26
KR20150008503A (ko) 2015-01-22
CN105315323A (zh) 2016-02-10
EP2215117A1 (en) 2010-08-11
JP2011502161A (ja) 2011-01-20
KR20100086015A (ko) 2010-07-29
HK1206753A1 (en) 2016-01-15
IL234901A0 (en) 2014-11-30
EP2215117B2 (en) 2018-01-10
EP2215117B1 (en) 2014-12-31
CY1116129T1 (el) 2017-02-08
US9896478B2 (en) 2018-02-20
RS53850B1 (sr) 2015-08-31
CA2703279C (en) 2014-04-22
PE20091434A1 (es) 2009-10-17
PL2565206T3 (pl) 2017-08-31
RU2498991C2 (ru) 2013-11-20
PL2215117T5 (pl) 2018-06-29
EP3441402A1 (en) 2019-02-13
CN101889025A (zh) 2010-11-17
DK2565206T3 (en) 2016-06-06
HK1221234A1 (zh) 2017-05-26
SI2215117T1 (sl) 2015-03-31
TWI448330B (zh) 2014-08-11
DK2215117T3 (en) 2015-03-02
EP2840090B1 (en) 2018-02-21
AU2008318865B2 (en) 2012-06-28
PL2215117T3 (pl) 2015-06-30
EP2840090A1 (en) 2015-02-25

Similar Documents

Publication Publication Date Title
CL2008003218A1 (es) Método para la purificación de un anticuerpo a partir de una composición que comprende el anticuerpo y al menos un contaminante.
AR062570A1 (es) Proceso para la purificacion de las proteinas que contienen fc
AR062711A1 (es) Lavado de arginina en l a purificacion de proteinas usando cromatografia de afinidad
ES2641179T3 (es) Montaje de un receptor en un concentrador de energía solar
CL2007001753A1 (es) Metodo para purificar rebaudiosida a sin refinar, mediante la combinacion con un solvente organico acuoso y posterior cristalizacion; y composicion farmaceutica que comprende los polimorfos.
PT2382656T (pt) Processo de separação para um sistema de camadas que compreende um wafer
DK2719388T3 (da) Borholdige små molekyler som antiinflammatoriske midler
DK2346888T3 (da) Fremgangsmåde til fremstilling af som SGLT-inhibitorer anvendelige forbindelser
DK2848625T3 (da) Fremgangsmåder til fjernelse af en kontaminant under anvendelse af ion bytningsmembrankromatografi med forskydning af naturligt forekommende proteiner
ES2498822T3 (es) Partículas poliméricas sensibles a la temperatura en aplicaciones de separación de proteínas
CU20150149A7 (es) Un modulador de la gmp-amp cíclico sintasa (cgas), composiciones farmacéuticas del mismo, y métodos para diseñar o caracterizar un modulador de cgas
CU23795A3 (es) Formulaciones líquidas de anticuerpo antirrábico
AR080506A1 (es) Composiciones detergentes liquidas que comprenden amido gelificantes de ph modificable y procesos para fabricarlos
DK2139892T3 (da) Substituerede pyrimidodiazepiner nyttige som PLK1-inhibitorer
BR112013012169B8 (pt) composição de líquido de lavagem para absorção de comtaminates ácidos de fluidos em um processo industrial e processo de redução de contaminantes ácidos em um fluxo de fluidos industrial
DK2291329T3 (da) Apparatur til rensning af væsker, især ballastvand
BRPI0810931A2 (pt) Método para o tratamento da lama na purificação da água
PT1917029E (pt) Um método de tratamento de células cancerígenas para criar uma célula cancerígena modificada que provoca uma resposta imunogénica
BRPI0920590A2 (pt) sistema para o processo térmico de peças a usinar
BR112018015267A2 (pt) método e composição para remover sujeiras, rótulos e outro material adesivo de uma superfície.
CO7101227A2 (es) Procedimiento de remojo previo mejorado para la conversión de biomasa
BRPI0812721A2 (pt) Processo para isolar um ou mais compostos alvo de um líquido aquoso, processo de multietapas para isolar um ou mais compostos alvo, e, método para isolar pelo menos um anticorpo de um líquido
CL2008003095A1 (es) Procedeimiento de preparacion de dihidrotienopirimidas; uno de los compuestos intermediarios considerados; y el procedimiento de preparacion de dicho compuesto intermediario.
CO7461129A2 (es) Beta-glucosidasa de magnaporthe grisea
CL2007003041A1 (es) Compuesto inhibidor de proteina quinasa activada por mitogeno; proceso para obtener dicho compuesto; compuesto intermediario; composicion farmaceutica que comprende dicho compuesto inhibidor; kit que comprende dicho compuesto; y uso de un compuesto p